There has been also development of small molecule inhibitors as well as use of natural and synthetic compounds in targeting Bcl-2 anti-apoptotic members which have remained mostly preclinical with the exception of a particular antisense oligo in Phase 3 for treatment of leukemia, melanoma, multiple myelomas, and non-small lung cancer [80-81]. This evidence concerns the gene BCL2 and plasma cell myeloma.